Studi accademici aperti all'arruolamento:

- INT52/10: A Phase 2 study of neoadjuvant cisplatin and gemcitabine plus Sorafenib for patients with transitional-cell carcinoma of the bladder (NCT01222676).
- INT38/10: Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment (NCT01172912).
- HER-URO01: Phase 2 study of the pan-HER inhibitor Dacomitinib (PF-0299804) in locally advanced or metastatic squamous cell carcinoma of the penis (NCT01728233).
- FM-12-GCT01: Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial (NCT01851200).
- PAZOTEST-01: Phase 2 study Pazopanib monotherapy for patients with relapsed or refractory germ-cell tumors (GCT) (NCT01743482).
- A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract.

Studi di prossima apertura:

- A Phase 2 study of the Aurora kinase A inhibitor Alisertib (MLN8237) in patients with relapsed or refractory transitional-cell carcinoma of the bladder and urothelial tract.
- A randomized, double-blind, placebo-controlled, Phase 2 study of Paclitaxel and Panitumumab in patients with relapsed or refractory, epidermal growth-factor receptor positive urothelial cancer.
- A Phase II, multicenter, single-arm study of MPDL3280A in patients with locally advanced or metastatic urothelial bladder cancer.

Progetti di ricerca traslazionale:

- *INT48/13 – Personalizing antiangiogenic treatment in advanced urothelial cancer.* This is a collaboration project with Memorial Sloan-Kettering Cancer Center. The proposed project will involve the genomic analysis of extreme responders in patients treated with prospective clinical trials in advanced urothelial carcinoma using advanced genomic technology (whole exome sequencing). The objective will be to understand the molecular basis of therapeutic response. The ultimate goal of this work is to develop trials enriched in patients with the genomic alterations predictive of response, leading to improved clinical benefit.

- *RUAB2012-11 – Retrospective study of prognostic factors in advanced urologic cancers (P.I. Guru Sonpavde)*. The proposed collaboration will involve the genomic analysis of patients with advanced squamous cell carcinoma of the penis receiving first-line chemotherapy. The project will rely on the advanced genomic technology available at UAB at Birmingham, Alabama, USA.

Studi retrospettivi multicentrici in fase di raccolta dati:

- *Hematopoietic stem cell collection and engraftment results in patients with germ cell tumours (GCT) who are candidates to myeloablative chemotherapy: a retrospective analysis from the Solid Tumours Working Party of the European Blood and Marrow Transplantation (EBMT) database.*